This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA
by Zacks Equity Research
The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.
Oxygen from Earnings: Global Week Ahead
by John Blank
In the Global Week Ahead, Q4 S&P500 earnings will supply the latest details on how major global companies are dealing with rising wage cost pressures.
Gilead (GILD) Drug Gets FDA Nod for Non-Hospitalized COVID Patients
by Zacks Equity Research
Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
by Zacks Equity Research
AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.
Best Growth Stocks to Buy for January 24th
by Zacks Equity Research
WLK, PFE, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 24, 2022
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
by Zacks Equity Research
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.
Pharma Stock Roundup: GSK's Consumer Unit Offer Rejection, FDA Updates for AZN, PFE
by Kinjel Shah
Glaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.
OPKO's (OPK) NGENLA Approved by Japan's MHLW for GHD Treatment
by Zacks Equity Research
Latest approval for OPKO's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.
Best Growth Stocks to Buy for January 21st
by Zacks Equity Research
PFE, M, and ARCB made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 21, 2022
Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal (Revised)
by Zacks Equity Research
Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.
Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal
by Zacks Equity Research
Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.
Glaxo (GSK) Stock Down As Unilever Decides Not to Raise Offer
by Zacks Equity Research
Unilever decides that it will not raise its offer of $68 billion for Glaxo's (GSK) Consumer Healthcare business.
Valneva (VALN) Up as COVID-19 Jab Neutralizes Omicron Variant
by Zacks Equity Research
Three doses of Valneva's (VALN) inactivated COVID-19 vaccine candidate, VLA2001, neutralizes the Omicron variant of SARS-CoV-2, per data from preliminary lab studies. Shares rally.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $53.54, moving -1.05% from the previous trading session.
Will 2022 Be a Better Year for Biotech Than 2021? 3 Big Picks
by Kinjel Shah
Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.
Best Growth Stocks to Buy for January 19th
by Zacks Equity Research
PFE, M, and AN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 19, 2022
Why You Should Invest in Dividend Growth ETFs Now
by Neena Mishra
We highlight 3 ultra-cheap ETFs that focus on high quality dividend payers
Best Growth Stocks to Buy for January 18th
by Zacks Equity Research
BERY, M, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 18, 2022
Arena (ARNA) Stock Up in 6 Months on PFE Merger Deal & Pipeline
by Zacks Equity Research
Arena Pharmaceuticals' (ARNA) potential acquisition by Pfizer to enable it to advance the development of its pipeline, especially the company's lead candidate, etrasimod, for ulcerative colitis.
AstraZeneca (AZN) Enhertu sBLA Receives FDA Priority Tag
by Zacks Equity Research
AstraZeneca's (AZN) sBLA seeks approval of Enhertu for unresectable and/or metastatic HER2-positive metastatic breast cancer previously treated with an anti-HER2-based regimen.
5 Low-Beta High-Yielding Stocks to Buy in a Capricious Market
by Nalak Das
We have narrowed our search to five large-cap low-beta stocks with a solid dividend yield. These are: PFE, BAX, IBKR, PSA and CUBE.
Zacks Industry Outlook Highlights: Roche, Pfizer, AbbVie and Merck
by Zacks Equity Research
Roche, Pfizer, AbbVie and Merck are highlighted in this Industry Outlook article.
AbbVie's (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis
by Zacks Equity Research
FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 and above. This is the third indication for Rinvoq in the United States.
Glaxo (GSK) Rejects Unilever's $68B Bid for Consumer Business
by Zacks Equity Research
Glaxo (GSK) rejects an offer from Unilever to acquire its consumer business worth 50 billion pounds ($68 billion). However, Unilever is likely to pursue the acquisition of the business.
Pfizer's (PFE) Cibinqo Gets FDA Nod for Atopic Dermatitis
by Zacks Equity Research
After a series of delays, Pfizer's (PFE) oral JAK inhibitor, Cibinqo (abrocitinib), gets approval for treating adults with atopic dermatitis in the United States.